Clinical Trial Update: A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging [NA]

View source ↗

Summary

A ClinicalTrials.gov study at Xijing Hospital is evaluating 68Ga-NOTA-RCCB6 PET imaging for staging, therapeutic evaluation, and restaging of renal cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• 68Ga-NOTA-RCCB6 (68Ga-labeled NOTA-RCCB6 PET tracer)
• 68Ga-PSMA PET/CT (68Ga-PSMA PET/CT imaging agent)

Snippet

Sponsor: Xijing Hospital | Conditions: RCC, Renal Cell Cancer | NA | Status: RECRUITING